Castleark Management buys $37,549,439 stake in ABIOMED (ABMD)

ABIOMED (ABMD) : Castleark Management scooped up 236,920 additional shares in ABIOMED during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 303,577 shares of ABIOMED which is valued at $37,549,439.ABIOMED makes up approximately 1.14% of Castleark Management’s portfolio.

Other Hedge Funds, Including , Mycio Wealth Partners added ABMD to its portfolio by purchasing 41 company shares during the most recent quarter which is valued at $5,071.Turner Investments boosted its stake in ABMD in the latest quarter, The investment management firm added 16,000 additional shares and now holds a total of 39,000 shares of ABIOMED which is valued at $4,689,750. ABIOMED makes up approx 1.37% of Turner Investments’s portfolio. Essex Investment Management Co added ABMD to its portfolio by purchasing 3,918 company shares during the most recent quarter which is valued at $454,370. ABIOMED makes up approx 0.07% of Essex Investment Management Co’s portfolio.Falcon Point Capital reduced its stake in ABMD by selling 6,733 shares or 7.28% in the most recent quarter. The Hedge Fund company now holds 85,726 shares of ABMD which is valued at $9,941,644. ABIOMED makes up approx 1.67% of Falcon Point Capital’s portfolio.Yhb Investment Advisors boosted its stake in ABMD in the latest quarter, The investment management firm added 767 additional shares and now holds a total of 9,167 shares of ABIOMED which is valued at $1,065,664. ABIOMED makes up approx 0.23% of Yhb Investment Advisors’s portfolio.

ABIOMED closed down -0.09 points or -0.07% at $121.43 with 3,69,444 shares getting traded on Friday. Post opening the session at $121, the shares hit an intraday low of $120.35 and an intraday high of $122.06 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, ABIOMED reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.24. The company had revenue of $103.00 million for the quarter, compared to analysts expectations of $97.48 million. The company’s revenue was up 40.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.

Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.

Leave a Reply

ABIOMED - Is it time to Sell?

Top Brokerage Firms are advising their investors on ABIOMED. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.